Today's Portrait Highlights

MetGen Oy

MetGen is a Finnish company that develops disruptive enzymatic products that enable significant efficiency improvements in the pulp and paper and biofuels industries, as well as removal of toxic micro-pollutants from waste water. The company offers enzymatic solutions for the pre-treatment of a variety of lingo-cellulosic biomass. MetGen provides enzymes that dramatically save energy at the refining step in the pulp and paper industry. In the advanced biofuel sector, MetGen enables production of low cost lingo-cellulosic sugars. MetGen's competitive advantage is the ability to tailor or adapt enzymes to meet each customer’s segment specific needs.

ScanBalt BioRegion

ScanBalt BioRegion comprises the Nordic and Baltic countries, northern Germany, northern Netherlands and north-western part of Russia. There are more than 60 universities and over 2100 life science/biotech companies including ~700 research based biotech SME´s in ScanBalt BioRegion. The non profit association ScanBalt™ fmba is a service provider for the members and promotes the development of ScanBalt BioRegion as a globally competitive health and bio economy. Core member services are promotion, project support and public affairs. ScanBalt™ fmba has existed since 2001.

The Region Zealand hospitals

The Region Zealand hospitals welcome medical device companies to test and cooperate on innovative solutions. A simple “One Entry” access point ensures that all demands are immediately directed towards the relevant department. The Region Zealand hospitals are available as test beds / living labs for start-ups, SMEs and other companies wishing to have access to healthcare data as well as to staff and patients for co-developing and testing new care products and solutions. User involvement is key and new projects must be based on innovation needs identified by the healthcare staff, patients and citizens. Keywords: One entry, hospitals, medical devices, test, co-creation, needs-based.